JAK inhibitor has the amelioration effect in lupus-prone mice: The involvement of IFN signature gene downregulation

BMC Immunology

Volumn 18, Issue 1, 2017, Pages

  Ikeda, Keigo ^a,b   Hayakawa, Kunihiro ^b   Fujishiro, Maki ^b   Kawasaki, Mikiko ^b   Hirai, Takuya ^b   Tsushima, Hiroshi ^c   Miyashita, Tomoko ^c   Suzuki, Satoshi ^a   Morimoto, Shinji ^a,b   Tamura, Naoto ^c   Takamori, Kenji ^b   Ogawa, Hideoki ^b   Sekigawa, Iwao ^a,b  

^a JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokines; Interferon; JAK STAT pathway; Systemic lupus erythematosus; T cells; Translational research

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERFERON; JANUS KINASE; JANUS KINASE INHIBITOR; STAT PROTEIN; STEROID; TOFACITINIB; 5-(TETRADECYLOXY)-2-FURANCARBOXYLIC ACID; ANTIINFLAMMATORY AGENT; CYTOKINE; FURAN DERIVATIVE; IFIT3 PROTEIN, HUMAN; IFIT3 PROTEIN, MOUSE; PROTEIN; SIGNAL PEPTIDE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; EFFECTOR CELL; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MEMORY T LYMPHOCYTE; MOUSE; NEPHRITIS; NONHUMAN; NZBXNZW F1 MOUSE; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NEW ZEALAND BLACK MOUSE; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DEXAMETHASONE; DOWN-REGULATION; FEMALE; FURANS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; MICE, INBRED NZB; MIDDLE AGED; PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; YOUNG ADULT;

EID: 85027989093     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/s12865-017-0225-9     Document Type: Article

References (33)

1. Sekigawa I, Kawasaki M, Ogasawara H, Kaneda K, Kaneko H, Takasaki Y, Ogawa H. DNA methylation: its contribution to systemic lupus erythematosus. Clin Exp Med. 2006;6(3):99-106.
2. Kawasaki M, Sekigawa I, Nozawa K, Kaneko H, Takasaki Y, Takamori K, Ogawa H. Changes in the gene expression of peripheral blood mononuclear cells during the menstrual cycle of females is associated with a gender bias in the incidence of systemic lupus erythematosus. Clin Exp Rheumatol. 2009;27(2):260-6.
3. Sekigawa I, Naito T, Hira K, Mitsuishi K, Ogasawara H, Hashimoto H, Ogawa H. Possible mechanisms of gender bias in SLE: a new hypothesis involving a comparison of SLE with atopy. Lupus. 2004;13(4):217-22.
4. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8(6):492-502.
5. Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol. 2012;2012:347141.
6. Du Z, Wei L, Murti A, Pfeffer SR, Fan M, Yang CH, Pfeffer LM. Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway. J Cell Biochem. 2007;102(5):1087-94.
7. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542-50.
8. Kawasaki M, Fujishiro M, Yamaguchi A, Nozawa K, Kaneko H, Takasaki Y, Takamori K, Ogawa H, Sekigawa I. Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus. 2011;20(12):1231-9.
9. Borie DC, O'Shea JJ, Changelian PS. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med. 2004;10(11):532-41.
10. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60(7):1895-905.
11. Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, Kwok K, Lukic T, Mortensen E. Ponce de Leon D et al: tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2015;
12. Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res. 2014;2014:283617.
13. Aringer M, Smolen JS. Safety of off-label biologicals in systemic lupus erythematosus. Expert Opin Drug Saf. 2015;14(2):243-51.
14. Aytan J, Bukhari MA. Use of biologics in SLE: a review of the evidence from a clinical perspective. Rheumatology (Oxford). 2015;
15. Seegal BC, Accinni L, Andres GA, Beiser SM, Christian CL, Erlanger BF, Hsu K. Immunologic studies of autoimmune disease in NZB-NZW F1 mice. I. Binding of fluorescein-labeled antinucleoside antibodies in lesions of lupus-like nephritis. J Exp Med. 1969;130(2):203-16.
16. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241-50.
17. Vila L, Roglans N, Baena M, Barroso E, Alegret M, Merlos M, Laguna JC. Metabolic alterations and increased liver mTOR expression precede the development of autoimmune disease in a murine model of lupus erythematosus. PLoS One. 2012;7(12):e51118.
18. Long H, Yin H, Wang L, Gershwin ME, Lu Q. The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. J Autoimmun. 2016;74:118-38.
19. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-61.
20. Yokoyama S, Perera PY, Terawaki S, Watanabe N, Kaminuma O, Waldmann TA, Hiroi T, Perera LP. Janus kinase inhibitor Tofacitinib shows potent efficacy in a mouse model of autoimmune lymphoproliferative syndrome (ALPS). J Clin Immunol. 2015;35(7):661-7.
21. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808.
22. Gertel S, Mahagna H, Karmon G, Watad A, Amital H. Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats. Clin Immunol. 2017;
23. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus. 2008;17(4):289-94.
24. Abe J, Ueha S, Suzuki J, Tokano Y, Matsushima K, Ishikawa S. Increased Foxp3(+) CD4(+) regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus. Am J Pathol. 2008;173(6):1682-92.
25. Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, Emilie D, Peltre G, Bensussan A, Bizzini B, et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A. 2009;106(13):5294-9.
26. Shaabani N, Honke N, Dolff S, Gorg B, Khairnar V, Merches K, Duhan V, Metzger S, Recher M, Barthuber C, et al. IFN-gamma licenses CD11b(+) cells to induce progression of systemic lupus erythematosus. J Autoimmun. 2015;62:11-21.
27. Kennedy WP, Maciuca R, Wolslegel K, Tew W, Abbas AR, Chaivorapol C, Morimoto A, McBride JM, Brunetta P, Richardson BC, et al. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med. 2015;2(1):e000080.
28. Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis JC Jr, Kennedy WP. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196-202.
29. Coit P, Jeffries M, Altorok N, Dozmorov MG, Koelsch KA, Wren JD, Merrill JT, McCune WJ, Sawalha AH. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun. 2013;43:78-84.
30. Tang J, Gu Y, Zhang M, Ye S, Chen X, Guo Q, Qian J, Bao C, Chen S, Shen N. Increased expression of the type I interferon-inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients. Lupus. 2008;17(9):805-13.
31. Kyogoku C, Smiljanovic B, Grun JR, Biesen R, Schulte-Wrede U, Haupl T, Hiepe F, Alexander T, Radbruch A, Grutzkau A. Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference? PLoS One. 2013;8(12):e83776.
32. D'Cunha J, Knight E Jr, Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A. 1996;93(1):211-5.
33. Care MA, Stephenson SJ, Barnes NA, Fan I, Zougman A, El-Sherbiny YM, Vital EM, Westhead DR, Tooze RM, Doody GM. Network analysis identifies Proinflammatory plasma cell polarization for secretion of ISG15 in human autoimmunity. J Immunol. 2016;197(4):1447-59.